Skip to main content
. 2017 Nov 9;12(11):e0187814. doi: 10.1371/journal.pone.0187814

Fig 4. Prognostic significance of SOX9 across several cancer types.

Fig 4

(A) 5-year relapse free survival rates in breast cancer patients. (B) 5-year progression free survival in ovarian cancer patients. 5-year survival rates in patients with (C) lung cancer and (D) gastric cancer.